{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:06:24Z","timestamp":1791266784718,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,2,18]],"date-time":"2014-02-18T00:00:00Z","timestamp":1392681600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s40262-014-0136-3","type":"journal-article","created":{"date-parts":[[2014,2,17]],"date-time":"2014-02-17T10:54:18Z","timestamp":1392634458000},"page":"565-580","source":"Crossref","is-referenced-by-count":89,"title":["Determination of an Optimal Dosing Regimen for Fexinidazole, a Novel Oral Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Studies"],"prefix":"10.1007","volume":"53","author":[{"given":"Antoine","family":"Tarral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Blesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf Valverde","family":"Mordt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"Torreele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Sassella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Bray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Hovsepian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Ev\u00e8ne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Gualano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Felices","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Strub-Wourgaft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,18]]},"reference":[{"key":"136_CR1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0140-6736(09)60829-1","volume":"375","author":"R Brun","year":"2010","unstructured":"Brun R, Blum J, Chappuis F, Burri C. Human African trypanosomiasis. Lancet. 2010;375:148\u201359.","journal-title":"Lancet"},{"key":"136_CR2","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/sj.bjp.0707354","volume":"152","author":"MP Barrett","year":"2007","unstructured":"Barrett MP, Boykin DW, Brun R, Tidwell RR. Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br J Pharmacol. 2007;152:1155\u201371.","journal-title":"Br J Pharmacol"},{"key":"136_CR3","unstructured":"Joubert J. Report of a WHO meeting on elimination of African trypanosomiasis (Trypanosoma brucei gambiense). Geneva, 3\u20135 December 2012. Geneva: WHO; 2013. p. 1754\u2013824."},{"key":"136_CR4","doi-asserted-by":"crossref","first-page":"e1950","DOI":"10.1371\/journal.pntd.0001950","volume":"6","author":"E Hasker","year":"2012","unstructured":"Hasker E, Lutumba P, Chappuis F, Kande V, Potet J, De Weggheleire A, et al. Human African trypanosomiasis in the Democratic Republic of the Congo: a looming emergency? PLoS Negl Trop Dis. 2012;6:e1950.","journal-title":"PLoS Negl Trop Dis"},{"key":"136_CR5","unstructured":"World Health Organization. Control and surveillance of human African trypanosomiasis: report of a WHO expert committee. WHO Technical Report Series 984. Geneva: WHO; 2013."},{"key":"136_CR6","doi-asserted-by":"crossref","first-page":"195040","DOI":"10.1155\/2009\/195040","volume":"2009","author":"CJ Bacchi","year":"2009","unstructured":"Bacchi CJ. Chemotherapy of human African trypanosomiasis. Interdiscip Perspect Infect Dis. 2009;2009:195040.","journal-title":"Interdiscip Perspect Infect Dis"},{"key":"136_CR7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","volume":"374","author":"G Priotto","year":"2009","unstructured":"Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, Arnold U, et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet. 2009;374:56\u201364.","journal-title":"Lancet"},{"key":"136_CR8","doi-asserted-by":"crossref","first-page":"e1920","DOI":"10.1371\/journal.pntd.0001920","volume":"6","author":"C Schmid","year":"2012","unstructured":"Schmid C, Kuemmerle A, Blum J, Ghabri S, Kande V, Mutombo W, et al. In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness. PLoS Negl Trop Dis. 2012;6:e1920.","journal-title":"PLoS Negl Trop Dis"},{"key":"136_CR9","doi-asserted-by":"crossref","first-page":"e923","DOI":"10.1371\/journal.pntd.0000923","volume":"4","author":"E Torreele","year":"2010","unstructured":"Torreele E, Bourdin Trunz B, Tweats D, Kaiser M, Brun R, Mazue G, et al. Fexinidazole\u2014a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010;4:e923.","journal-title":"PLoS Negl Trop Dis"},{"key":"136_CR10","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1128\/AAC.00246-11","volume":"55","author":"M Kaiser","year":"2011","unstructured":"Kaiser M, Bray MA, Cal M, Bourdin Trunz B, Torreele E, Brun R, et al. Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. Antimicrob Agents Chemother. 2011;55:5602\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"136_CR11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/mutage\/ges015","volume":"27","author":"D Tweats","year":"2012","unstructured":"Tweats D, Bourdin Trunz B, Torreele E. Genotoxicity profile of fexinidazole\u2014a drug candidate in clinical development for human African trypanomiasis (sleeping sickness). Mutagenesis. 2012;27:223\u201332.","journal-title":"Mutagenesis"},{"key":"136_CR12","doi-asserted-by":"crossref","first-page":"119re1","DOI":"10.1126\/scitranslmed.3003326","volume":"4","author":"S Wyllie","year":"2012","unstructured":"Wyllie S, Patterson S, Stojanovski L, Simeons FRC, Norval S, Kime R, et al. The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis. Sci Transl Med. 2012;4:119re1.","journal-title":"Sci Transl Med"},{"key":"136_CR13","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1073\/pnas.0711014105","volume":"105","author":"SR Wilkinson","year":"2008","unstructured":"Wilkinson SR, Taylor MC, Horn D, Kelly JM, Cheeseman I. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci U\u00a0S\u00a0A. 2008;105:5022\u20137.","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"136_CR14","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1128\/AAC.00332-10","volume":"54","author":"AY Sokolova","year":"2010","unstructured":"Sokolova AY, Wyllie S, Patterson S, Oza SL, Read KD, Fairlamb AH. Cross-resistance to nitro-drugs and implications for the treatment of human African trypanosomiasis. Antimicrob Agents Chemother. 2010;54:2893\u2013900.","journal-title":"Antimicrob Agents Chemother"},{"key":"136_CR15","unstructured":"ICH harmonised tripartite guideline for good clinical practice E6(R1). http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6_R1\/Step4\/E6_R1__Guideline.pdf . Accessed 11 Feb 2011."},{"key":"136_CR16","unstructured":"Tarral A, Valverde O, Blesson S, Strub-Wourgaft N, Hosvepian L, Evene E. Single-dose safety and pharmacokinetics of fexinidazole in healthy subjects. 7th European Congress on Tropical Medicine & International Health; 3\u20136 Oct 2011; Barcelona. http:\/\/www.dndi.org\/media-centre\/events\/events-2011\/216-media-centre\/events\/980-barcelona.html . Accessed 11 Feb 2011."},{"key":"136_CR17","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/009286159502900324","volume":"29","author":"K Gough","year":"1995","unstructured":"Gough K, Hutchison M, Keene O, Byrom B, Ellis S, Lacey L, et al. Assessment of dose proportionality: report from the Statisticians in the Pharmaceutical Industry\/Pharmacokinetics UK Joint Working Party. Drug Inf J. 1995;29:1039\u201348.","journal-title":"Drug Inf J"},{"key":"136_CR18","unstructured":"Note for guidance on clinical safety data management: definitions and standards for expedited reporting (CPMP\/ICH\/377\/95); 2006. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002749.pdf . Accessed 11 Feb 2011."},{"key":"136_CR19","doi-asserted-by":"crossref","unstructured":"Amidon G, Lennern\u00e4s H, Shah V, Crison J. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413\u201320.","DOI":"10.1023\/A:1016212804288"},{"key":"136_CR20","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1177\/0091270008323261","volume":"48","author":"M Malik","year":"2008","unstructured":"Malik M, Hnatkova K, Ford J, Madge D. Near-thorough QT study as part of a first-in-man study. J Clin Pharmacol. 2008;48:1146\u201357.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"136_CR21","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00003088-199936050-00004","volume":"36","author":"KC Lamp","year":"1999","unstructured":"Lamp KC, Freeman CD, Klutman NE, Lacy MK. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet. 1999;36(5):353\u201373.","journal-title":"Clin Pharmacokinet"},{"key":"136_CR22","doi-asserted-by":"crossref","unstructured":"Sp\u00e9nard J, Aumais C, Massicotte J, Brunet J-S, Tremblay C, Grace M, et al. Effects of food and formulation on the relative bioavailability of bismuth biskalcitrate, metronidazole, and tetracycline given for Helicobacter pylori eradication. Br J Clin Pharmacol. 2005;60:374\u20137.","DOI":"10.1111\/j.1365-2125.2005.02441.x"},{"key":"136_CR23","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2165\/00003088-199223050-00002","volume":"23","author":"AH Lau","year":"1992","unstructured":"Lau AH, Lam NP, Piscitelli SC, Wilkes L, Danziger LH. Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin Pharmacokinet. 1992;23:328\u201364.","journal-title":"Clin Pharmacokinet"},{"key":"136_CR24","unstructured":"Mission Pharmacal Company. Tindamax (tinidazole) tablet, film coated for oral use. Daily Med; 2007. http:\/\/dailymed.nlm.nih.gov\/dailymed\/archives\/fdaDrugInfo.cfm?archiveid=5060 . Accessed 11 Feb 2011."},{"key":"136_CR25","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/clpt.1989.204","volume":"46","author":"DL Hughes","year":"1989","unstructured":"Hughes DL, Barker KB, Patel RK, Spillers CR, Watts KC, Batts DHE. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Clin Pharmacol Ther. 1989;46:674\u201385.","journal-title":"Clin Pharmacol Ther"},{"key":"136_CR26","unstructured":"Zimmerman HJ. Drug-induced liver disease. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999. p. 427\u201357."},{"key":"136_CR27","unstructured":"FDA\/CDER\/CBER. Guidance for industry. Drug-induced liver injury: premarketing clinical evaluation. Rockville: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER); 2009."},{"key":"136_CR28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1365-2125.1999.00952.x","volume":"48","author":"P Rosenzweig","year":"1999","unstructured":"Rosenzweig P, Miget T, Brohier S. Transaminase elevation on placebo during phase I trials: prevalence and significance. Br J Clin Pharmacol. 1999;48:19\u201323.","journal-title":"Br J Clin Pharmacol"},{"key":"136_CR29","unstructured":"Gualano V, Felices M, Evene E, Blesson S, Tarral A. Dose regimen assessment for oral fexinidazole [abstract no. 2572]. PAGE. Abstracts of the annual meeting of the Population Approach Group in Europe. ISSN 1871-6032; 2012. p. 21. http:\/\/www.page-meeting.org\/?abstract=2572 . Accessed 11 Feb 2011."},{"key":"136_CR30","doi-asserted-by":"crossref","unstructured":"Bahia MT, de Andrade IM, Martins TAF, do Nascimento \u00c1FDS, Diniz LDF, Caldas IS, et al. Fexinidazole: a potential new drug candidate for Chagas disease. PLoS Negl Trop Dis. 2012;6:e1870.","DOI":"10.1371\/journal.pntd.0001870"},{"key":"136_CR31","unstructured":"Winkelmann E, Raether W. New chemotherapeutically active nitroimidazoles. Curr Chemother Infect Dis, Proc 11th Int Congr Chemother. 1980;2:969\u201370."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-014-0136-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-014-0136-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-014-0136-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T14:02:07Z","timestamp":1565186527000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-014-0136-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,18]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["136"],"URL":"https:\/\/doi.org\/10.1007\/s40262-014-0136-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,18]]}}}